IRIS UniCatt

Gori, Niccolo'
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 1.234
NA - Nord America 1.142
EU - Europa 648
SA - Sud America 223
AF - Africa 42
OC - Oceania 3
Totale 3.292
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.082
SG - Singapore 560
CN - Cina 274
BR - Brasile 182
VN - Vietnam 136
IT - Italia 116
FR - Francia 111
DE - Germania 102
SE - Svezia 72
GB - Regno Unito 56
HK - Hong Kong 40
FI - Finlandia 39
IN - India 38
JP - Giappone 36
ID - Indonesia 34
IE - Irlanda 33
CA - Canada 32
RU - Federazione Russa 26
PL - Polonia 23
KR - Corea 22
MX - Messico 20
BD - Bangladesh 18
SA - Arabia Saudita 18
NL - Olanda 15
IQ - Iraq 13
AR - Argentina 12
ZA - Sudafrica 12
CI - Costa d'Avorio 11
PK - Pakistan 11
ES - Italia 9
AT - Austria 8
CZ - Repubblica Ceca 7
BO - Bolivia 6
EC - Ecuador 6
KE - Kenya 6
VE - Venezuela 6
MA - Marocco 5
TR - Turchia 5
AL - Albania 4
BE - Belgio 4
CY - Cipro 4
LT - Lituania 4
AE - Emirati Arabi Uniti 3
AU - Australia 3
CO - Colombia 3
DZ - Algeria 3
HR - Croazia 3
PA - Panama 3
PE - Perù 3
PS - Palestinian Territory 3
PT - Portogallo 3
RO - Romania 3
UA - Ucraina 3
UZ - Uzbekistan 3
CL - Cile 2
HU - Ungheria 2
IL - Israele 2
JO - Giordania 2
MY - Malesia 2
PH - Filippine 2
UY - Uruguay 2
AO - Angola 1
AZ - Azerbaigian 1
BG - Bulgaria 1
BN - Brunei Darussalam 1
CR - Costa Rica 1
DK - Danimarca 1
EG - Egitto 1
ET - Etiopia 1
GD - Grenada 1
GE - Georgia 1
GY - Guiana 1
HN - Honduras 1
IR - Iran 1
JM - Giamaica 1
KW - Kuwait 1
LA - Repubblica Popolare Democratica del Laos 1
LU - Lussemburgo 1
LV - Lettonia 1
MD - Moldavia 1
NG - Nigeria 1
NI - Nicaragua 1
SN - Senegal 1
SY - Repubblica araba siriana 1
TM - Turkmenistan 1
Totale 3.292
Salva come PNG Salva come JPEG
Città #
Singapore 304
San Jose 158
Ashburn 125
Chandler 122
Beijing 59
Hefei 55
Ho Chi Minh City 44
Frankfurt am Main 41
New York 41
Lauterbourg 38
Hong Kong 37
Los Angeles 36
Milan 36
Dublin 32
Tokyo 32
Jakarta 31
Hanoi 29
Helsinki 24
Rome 23
Munich 22
Seoul 20
Council Bluffs 19
Dallas 19
Kent 18
London 18
St Louis 18
Bremen 17
Boston 16
Paris 16
Boardman 15
Warsaw 15
Chicago 14
Moscow 14
São Paulo 14
Amsterdam 13
Hangzhou 12
Princeton 12
Santa Clara 12
Abidjan 11
The Dalles 11
Tukwila 11
Jeddah 10
Montreal 10
Brooklyn 9
Lappeenranta 9
Nuremberg 9
Da Nang 8
Denver 8
Roubaix 8
Stockholm 8
Boydton 7
Hyderabad 7
Mexico City 7
Chennai 6
Curitiba 6
Manchester 6
Mumbai 6
Nairobi 6
Orem 6
Ottawa 6
Portsmouth 6
Pune 6
Redwood City 6
Toronto 6
Turku 6
Washington 6
Wilmington 6
Wroclaw 6
Atlanta 5
Falkenstein 5
Haiphong 5
Rio de Janeiro 5
San Mateo 5
Southampton 5
Vienna 5
Baghdad 4
Brussels 4
Düsseldorf 4
Johannesburg 4
La Paz 4
Nicosia 4
North Bergen 4
San Francisco 4
Bexley 3
Brasília 3
Brno 3
Bắc Ninh 3
Bến Tre 3
Caracas 3
Charlotte 3
Chiyoda-ku 3
Cleveland 3
Faisalabad 3
Houston 3
Indaiatuba 3
Medina 3
Panama City 3
Phoenix 3
Poplar 3
Porto Alegre 3
Totale 1.912
Salva come PNG Salva come JPEG
Nome #
Assessment of alopecia areata universalis successfully treated with upadacitinib 124
Therapeutic impact and management of persistent head and neck atopic dermatitis in dupilumab-treated patients 124
Periocular molluscum contagiosum in an atopic dermatitis patient treated with upadacitinib 118
Dupilumab-associated ocular adverse events are predicted by low tear break-up time and correlate with high IL-33 tear concentrations in patients with atopic dermatitis 114
Successful Combination of Systemic Agents for the Treatment of Atopic Dermatitis Resistant to Dupilumab Therapy 114
Dupilumab improves clinical manifestations, symptoms and quality of life in adult patients with chronic nodular prurigo 113
Biological agents targeting interleukin-13 for atopic dermatitis 112
Disease Severity Is Associated with Alexithymia in Patients with Atopic Dermatitis 111
Evaluation of Upadacitinib efficacy in the treatment of Atopic Dermatitis of sensitive areas 110
Dupilumab therapy of atopic dermatitis of the elderly: a multicentre, real-life study 105
Long-term Effectiveness and Safety of Upadacitinib for Atopic Dermatitis in a Real-world Setting: An Interim Analysis Through 48 Weeks of Observation 102
Histological features of immune cell infiltrate in lesional skin correlate with therapeutic response to dupilumab 100
Management of patients with atopic dermatitis undergoing systemic therapy during COVID-19 pandemic in Italy: Data from the DA-COVID-19 registry 98
Head and neck atopic dermatitis: still a challenging manifestation in the biologic era 98
Successful response of upadacitinib in different clinical phenotypes of atopic dermatitis 97
Analysis of predictive factors influencing dupilumab continuation rate in adult patients with atopic dermatitis: results from an Italian multicenter study 96
Gianotti-Crosti Syndrome after SARS-CoV-2 infection 95
Effectiveness and Safety of Long-Term Dupilumab Treatment in Elderly Patients with Atopic Dermatitis: A Multicenter Real-Life Observational Study 94
A case of disseminated perforating necrobiosis lipoidica 91
Leser-Trélat sign as a rare manifestation of cutaneous melanoma 90
Association between maternal dupilumab exposure and pregnancy outcomes in patients with moderate-to-severe atopic dermatitis: A nationwide retrospective cohort study 89
Low grade of satisfaction related to the use of current systemic therapies among pustular psoriasis patients: a therapeutic unmet need to be fulfilled 85
Successful response to upadacitinib in the treatment of atopic dermatitis lesions involving sensitive and visible areas resistant to dupilumab treatment 84
Correction to: Comorbidities and treatment patterns in adult patients with atopic dermatitis: results from a nationwide multicenter study (Archives of Dermatological Research, (2022), 314, 6, (593-603), 10.1007/s00403-021-02243-w) 82
The psychological burden during COVID-19 pandemic in a cohort of patients affected by moderate-to-severe atopic dermatitis treated with dupilumab 81
Comorbidities and treatment patterns in adult patients with atopic dermatitis: results from a nationwide multicenter study 78
Identification of clinical predictors for dupilumab dose spacing in adults with atopic dermatitis: a real-world study 73
A case of guttate psoriasis during treatment with dupilumab 73
Current treatment goals are achieved by the majority of patients with atopic dermatitis treated with tralokinumab: results from a multicentric, multinational, retrospective, cohort study 71
Polymorphic Skin Eruption in a Middle-Aged Man: A Quiz 71
Successful response to tralokinumab in patients unresponsive, intolerant or with contraindications to dupilumab and JAK inhibitors: A case series 68
Annular elastolytic giant cell granuloma following herpes zoster infection 68
Effectiveness and Safety of Upadacitinib in the Treatment of Moderate-Severe Atopic Dermatitis: A Multicentric, Prospective, Real-World, Cohort Study 68
Patient Satisfaction with Calcipotriol/Betamethasone Dipropionate Cream in Psoriatic Patients Previously Treated With Foam Vehicle 63
Response to the article by Narla et al “Management of inadequate response and adverse effects to dupilumab in atopic dermatitis” 62
National Information Campaign Revealed Disease Characteristic and Burden in Adult Patients Suffering from Atopic Dermatitis 61
Use of upadacitinib in the treatment of moderate to severe atopic dermatitis: patient profiling, dose selection, and therapy modulation, what does real-life teach us? 59
Safety and Effectiveness Profile of Dupilumab in the Treatment of Atopic Dermatitis in Special Populations 3
Baricitinib for adult atopic dermatitis: real-world effectiveness, safety, and response predictors 3
Totale 3.348
Salva come PNG Salva come JPEG
Categoria #
all - tutte 16.009
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 16.009
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202271 2 0 0 3 4 2 4 6 0 7 18 25
2022/2023359 27 52 24 54 25 38 24 49 47 4 13 2
2023/2024321 15 42 47 31 23 40 24 8 11 8 39 33
2024/2025717 11 10 59 14 75 32 25 15 85 75 189 127
2025/20261.820 231 68 129 238 299 87 321 90 110 133 63 51
2026/202720 20 0 0 0 0 0 0 0 0 0 0 0
Totale 3.348